FDA– tag –
-
Intellia Therapeutics Sees Steady Progress with HAE Therapy Lonvo-Z and ATTR Amyloidosis Therapy Nex-Z; FDA Lifts Clinical Hold on Nex-Z
Seeking Alpha USA Overview Intellia Therapeutics has demonstrated steady progress in the clinical development of Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Positive data reported from the Phase 3 HAELO study ... -
FDA Issues New Draft Guidance to Accelerate Cell and Gene Therapy Development: Promoting Efficiency Through Prior Knowledge Utilization
FDA Press Announcements USA Overview The FDA announced new draft guidance on June 2, 2026, aimed at accelerating the development of cell and gene therapies. This guidance encourages sponsors to effectively leverage 'prior knowledge,' par... -
CRISPR Gene Editing Utilized: First Leishmaniasis Vaccine Receives FDA IND Approval, Advancing to Phase 1 Clinical Trial
Ohio State News USA Overview The first leishmaniasis vaccine, developed by researchers at Ohio State University, is set to begin a Phase 1 clinical trial after receiving Investigational New Drug (IND) approval from the FDA. This innovati... -
Beam Therapeutics Stock Rises 2.04% After Receiving Triangle Business Journal’s 2026 Life Sciences Award, Signaling Heightened Market Optimism
Traders Union USA Overview Beam Therapeutics received the prestigious 2026 Life Sciences Award from Triangle Business Journal, acknowledging its innovative contributions. Concurrently, the company's stock experienced a 2.04% rise, reflec... -
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
FDA-Cleared AI “Artera AI Breast” Demonstrates Clinical Utility for Breast Cancer Prognosis and Chemotherapy Benefit Prediction at ASCO 2026
The Pathologist USA Overview At ASCO 2026, a study showcased the utility of Artera AI Breast, an FDA-cleared multimodal artificial intelligence model, for predicting prognosis and chemotherapy benefit in postmenopausal women with node-po... -
LEX Diagnostics Revolutionizes Infectious Disease Testing with Ultra-Rapid PCR POCT System
MTEC UK Overview LEX Diagnostics, a molecular diagnostics company, is developing an ultra-rapid, high-sensitivity PCR Point-of-Care Testing (POCT) system designed to deliver lab-quality results within minutes. Focusing on infectious dise... -
Abbott Secures CE Mark for World’s First Dual Glucose-Ketone Sensor, Revolutionizing DKA Management
MedTech Dive USA Overview Abbott has received European CE Mark approval for its Libre Duo and Libre Duo 10 Day systems, the world's first dual-analyte sensors capable of continuously measuring both glucose and ketones. This technology ai... -
Ōura Ring to Integrate Blood Pressure Monitoring Following FDA Policy Shift
MedTech Dive USA Overview The Ōura smart ring is set to roll out new health and wellness features in June, including a tool for tracking nocturnal blood pressure patterns, following a policy change by the FDA. This feature aims to show t... -
Dexcom CGM Receives FDA Breakthrough Designation for In-Hospital Glucose Monitoring
HCPLive USA Overview Dexcom's continuous glucose monitoring (CGM) technology has been granted Breakthrough Device Designation by the U.S. FDA for use in hospital settings. This landmark decision is poised to revolutionize inpatient gluco...
